logo-loader

BriaCell reports positive clinical data for breast cancer targeted immunotherapy

Published: 14:34 20 Feb 2018 EST

Bill Williams, President and CEO of BriaCell Therapeutics (CVE: BCT) tells Proactive Investors they believe they will literally "change the face of cancer immunotherapy."

Williams says BriaCell's approach is unique in that they have a personalized "off the shelf" approach to immunotherapy for cancer, targeting advanced breast cancer.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 4 minutes ago